Window of opportunity
For healthy symptomatic women under 60 or within 10 years of menopause, benefits of hormone therapy on quality of life, vasomotor symptoms, bone, and mood generally outweigh risks.
Bioidentical preference
Transdermal estradiol paired with oral micronized progesterone is now the preferred regimen — associated with a lower clot, stroke, and breast risk profile than the conjugated equine estrogens + medroxyprogesterone used in the original WHI arm.
Bone & cardiovascular protection
Timely HRT reduces fracture risk and, when started in the window, is associated with reduced coronary heart disease and all-cause mortality.
Testosterone for women
The 2019 Global Consensus Position Statement endorses physiologic testosterone for hypoactive sexual desire in postmenopausal women — a therapy still overlooked in conventional care.
Duration is individualized
There is no arbitrary stop date. Continuation is based on ongoing symptoms, risk profile, and shared decision-making with your provider.
Sources: The Menopause Society 2022 Hormone Therapy Position Statement; Manson et al. JAMA 2017 (WHI 18-year follow-up); Davis et al. Global Consensus Position Statement on Testosterone Therapy for Women, 2019.